Danish quantum company, Kvantify, has launched its first product, Kvantify koffee, aimed at revolutionizing drug discovery. The product uses computational methods to calculate a critical parameter in screening and selecting new drug candidates, potentially reducing the need for costly and time-consuming lab experiments. The company’s CEO, Hans Henrik Knudsen, and Head of Products & Strategy, Christina Krogsgård Nielsen, believe the product can significantly reduce risk in new medication development. Kvantify, established in 2022, is a leading quantum company providing software solutions for complex computational challenges in various industries.
Kvantify Introduces Computational Drug Discovery Tool
Kvantify, a Danish quantum company, has announced the launch of its first product, Kvantify koffee. This product is a computational tool designed to aid in drug discovery by calculating a critical parameter in screening and selecting new drug candidates: Unbinding Kinetics. The tool is designed to work with classical computers but is also prepared to offer increased value as quantum computer hardware matures.
Kvantify has a history of specializing in optimization and simulation across various industries, including pharmaceuticals, financial services, logistics, and telecommunications. The launch of Kvantify koffee marks their first commercial product, specifically targeted at the discovery of new medications.
A New Approach to Drug Discovery
Kvantify koffee is unique in its ability to simulate unbinding kinetics, a critical parameter in the drug discovery process. This simulation capability allows for faster and more accurate screening processes for new medications. The calculations for one molecule take only minutes, hence the product’s name. This speed and accuracy can potentially save time and money for the pharmaceutical industry and expedite the availability of new medications.
The tool aims to reduce the risk in the development of new medication by providing insights about unbinding kinetics earlier in the process. Currently, these kinetics are typically calculated through laboratory experiments, which can be expensive and time-consuming. Kvantify’s long-term vision is to reduce the time from Hit-ID to lead optimization by 75% and to increase the success rates of drug discovery.
Quantum Algorithm and Future Plans
Kvantify has previously introduced its quantum algorithm FAST-VQE, which is used within quantum chemistry. This algorithm shows high precision with fewer resources than previous quantum algorithms such as ADAPT-VQE, making it a significant contribution to the practical application of quantum computers.
Kvantify was established in 2022 by Hans Henrik Knudsen, Nikolaj Zinner, and Allan Grønlund. The company comprises more than 65 experts in quantum computing, supercomputing, cloud software, mathematics, chemistry, AI, and machine learning. The team is spread across offices in Copenhagen, Aarhus, and London, with plans to expand to the United States in 2024.
About Kvantify
Kvantify is a quantum company from Denmark that provides software solutions to tackle complex computational challenges in various industries, including pharmaceuticals, financial services, logistics, and telecommunications.
In addition to their product development, Kvantify is involved in several scientific quantum research projects. They are pushing the boundaries of what is possible with quantum computing, particularly through their collaboration with Amazon Web Services on the Braket platform.
External Link: Click Here For More
